Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7430793 | 0.98 | ERN1 (0.45) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL202290 | 0.80 | ERN1 (0.41) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6512051 | 0.80 | ERN1 (0.41) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29600703 | 0.80 | ERN1 (0.41) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5036447 | 0.80 | CRHBP (0.42) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18229829 | 0.79 | HSP90AA1 (0.41) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2178791 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL30557784 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL27732124 | 0.78 | KMT2A (0.41) | ERN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3991031 | 0.77 | HSP90AA1 (0.39) | MEN1KMT2AALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664764-A | Preparation method of 3-amino-2-hydroxypyridine | CHANGZHOU LEZGUE CHEMICAL CO LTD | 2014-03-26 | — | — | CN | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4406948-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-117957219-A | Pyridine derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023147545-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-08-03 | — | — | WO | disclosed |
| US-4640926-A | 3,5-Substituted-2-pyridylalkylaminothiadiazoles having histamine H1 -antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-02-03 | — | — | US | disclosed |
| EP-0107914-B1 | AMINOPYRIMIDINONE DERIVATIVES USEFUL AS HISTAMINE H1-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
| US-4537891-A | 2-(3,5-Substituted-2-pyridylalkylamino)-5-benzyl-4-pyrimidones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-08-27 | — | — | US | disclosed |
| US-4537890-A | 2-(3,5-Substituted-2-pyridylalkylamino)-5-oxopyridylmethyl-4-pyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-08-27 | — | — | US | disclosed |
| US-4532252-A | 3,5-Substituted-2-pyridylalkylamino compounds having histamine H1 -antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-30 | — | — | US | disclosed |
| EP-0134091-A1 | Pyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-03-13 | — | — | EP | disclosed |
| EP-0122109-A2 | Preparation of cyano- or aminoalkyl substituted aromatic amines | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-10-17 | — | — | EP | disclosed |
| EP-0115132-A1 | Pyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-08-08 | — | — | EP | disclosed |
| EP-0112142-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0107914-A1 | Aminopyrimidinone derivatives useful as histamine H1-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | ERN1 1576/4885MEN1 357/4885KMT2A 2353/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | ERN1 219/4885MEN1 678/4885KMT2A 1011/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ERN1 1541/4885MEN1 2317/4885KMT2A 1975/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | ERN1 1029/4885MEN1 3186/4885KMT2A 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.